Drug Type Small molecule drug |
Synonyms 埃索美拉唑镁/碳酸氢钠, 奥美拉唑镁碳酸氢钠, LJ01003 + [3] |
Target |
Action inhibitors |
Mechanism Proton pump inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (30 Sep 2022), |
Regulation- |
Molecular FormulaC34H36MgN6O6S2 |
InChIKeyKWORUUGOSLYAGD-UHFFFAOYSA-N |
CAS Registry95382-33-5 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hyperchlorhydria | China | 05 Jan 2026 | |
| Duodenal Ulcer | China | 08 May 2024 | |
| Erosive esophagitis | China | 08 May 2024 | |
| Stomach Ulcer | China | 08 May 2024 | |
| Gastroesophageal Reflux | China | 30 Sep 2022 | |
| Helicobacter pylori infection | China | 30 Sep 2022 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Esophagitis | Clinical | China | 11 Nov 2024 | |
| Esophagitis | Clinical | China | 11 Nov 2024 | |
| Esophagitis, Peptic | IND Approval | China | 03 Jul 2024 | |
| Esophagitis, Peptic | IND Approval | China | 03 Jul 2024 |





